This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Subarachnoid Haemorrhage — Acute Intensive Care, V268거미막하출혈 — 급성기 집중치료 (지주막하출혈 — 급성기 집중치료)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I60 (Subarachnoid haemorrhage)  |  Special Copayment Reduction: V268 (Special Copayment Reduction for acute-phase intensive care of cerebrovascular disease: intensive care unit admission, 5% copayment for up to 30 days)
B. SynonymsSubarachnoid hemorrhage, subarachnoid hemorrhage (SAH), aneurysmal SAH (aSAH), spontaneous subarachnoid hemorrhage
C. Adult onsetMost common at ages 40~65; slightly more common in women. There may be prodromal symptoms before rupture (sentinel headache), and acute onset is characteristic.
1. HistoryFrom Wepfer's description in the 16th century to the introduction of coil embolization; a summary of the historical development of aSAH intensive care.
2. CausesAbout 75~80% of spontaneous SAH is caused by cerebral aneurysm rupture; the rest are non-aneurysmal (perimesencephalic) SAH, AVM, dural AVF, vasculitis, etc.
3. GeneticsAssociated with genetic diseases such as ADPKD (PKD1, PKD2), EDS (COL3A1), NF1, and ACVRL1; familial clustering and some gene variants identified in sporadic aneurysms.
4. General epidemiologyAnnual incidence about 6~9 per 100,000 population; about 100,000 per year worldwide; incidence in Korea is about 10~15 per 100,000.
5. PathophysiologyAneurysm rupture → blood entering the subarachnoid space → sudden rise in intracranial pressure and early brain injury → a cascade of three major complications: vasospasm, delayed cerebral ischemia, and hydrocephalus.
6. SymptomsWorst headache of life (thunderclap headache), nausea and vomiting, neck stiffness, altered consciousness; a prodromal headache (sentinel headache) may precede it.
7. SignsSigns of meningeal irritation, decreased consciousness, pupillary abnormalities, fundal hemorrhage (Terson syndrome), ECG abnormalities, and others appear.
8. ScreeningNon-contrast CT is first-line; in CT-negative thunderclap headache, blood is confirmed by lumbar puncture or CT myelography.
9. DiagnosisCT + CTA or DSA confirm hemorrhage and determine aneurysm location and morphology. Severity is graded with the Hunt-Hess, WFNS, and Fisher scales.
10. TreatmentEarly aneurysm treatment (coil embolization, clip ligation), vasospasm prevention (nimodipine), hydrocephalus management (EVD), and intensive care unit management are key.
11. Prognosis30-day mortality about 30~40%; long-term neurocognitive impairment persists in about 30~50% of survivors; prognosis can be improved with early treatment.
12. PreventionSmoking cessation, hypertension control, selective MRA screening when family history is positive, and treatment decisions for unruptured aneurysms are the key prevention strategies.
13. ReferencesConnolly ES Jr et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage (AHA/ASA 2012) … and 9 other papers

1. History

The first clinical description of subarachnoid haemorrhage (SAH) dates back to the 17th century. The Swiss physician Johann Jacob Wepfer described cases of intracranial hemorrhage due to cerebral vessel rupture in Apoplexia in 1658, some of which are thought to correspond to subarachnoid hemorrhage. However, hemorrhage in the subarachnoid space came to be recognized as a separate clinical entity only in the 19th century. As the British neurologist John Cheyne (1812) and subsequently various pathologists described blood accumulation at the base of the brain, the characteristics of the disease were gradually clarified.

The association between cerebral aneurysm and SAH was established in the mid-to-late 19th century. In 1886, Bramwell described aneurysm rupture as the cause of SAH, and in the early 1900s Sir Victor Horsley of Britain explored the possibility of a surgical approach to cerebral aneurysms. Harvey Cushing and Norman Dott led early attempts at cerebral aneurysm surgery in the 1920s–1930s, and Walter Dandy's successful aneurysm clipping in 1937 opened a new chapter in neurosurgical treatment.

With the introduction of CT (1973), diagnosis of SAH during life was standardized, and advances in cerebral angiography (DSA) made it possible to determine the exact location and morphology of aneurysms. In 1973, Hunt and Hess published a clinical severity grading system, and in 1980 Fisher presented a classification system predicting the risk of vasospasm based on CT findings. In 1991, Guglielmi of Italy developed endovascular coil embolization using detachable coils (Guglielmi Detachable Coil, GDC), which fundamentally changed the paradigm of SAH treatment. In 2002, the ISAT (International Subarachnoid Aneurysm Trial) confirmed that coil embolization was superior or equivalent to surgical clipping in the proportion with mRS 0~2 at 1 year, establishing endovascular treatment as the main treatment for SAH. In 2023, the American Heart Association/American Stroke Association (AHA/ASA) published a revised guideline for the management of aneurysmal SAH, reflecting the latest evidence such as vasospasm management and the introduction of clazosentan.


2. Causes

The most common cause of spontaneous subarachnoid hemorrhage is cerebral aneurysm rupture, accounting for about 75~85% of the total. The remainder consists of non-aneurysmal causes.

Ruptured intracranial aneurysm: intracranial aneurysms form at arterial bifurcations on the basis of structural weak points in the vessel wall (absence of the internal elastic lamina, defects in medial smooth muscle). Saccular aneurysms are the most common, and the anterior communicating artery of the circle of Willis (about 30~35%), the origin of the posterior communicating artery (about 20~25%), and the middle cerebral artery bifurcation (about 20%) are the common sites. When hypertension, pulsatile flow, and oxidative stress are continuously applied to the aneurysm wall, the wall weakens and ruptures.

Non-aneurysmal perimesencephalic SAH (PMSAH): accounts for about 10~15% of all SAH, with hemorrhage confined to the space in front of the midbrain (pretruncal/perimesencephalic). The cause is unclear but is presumed to be venous in origin or a micro-arteriovenous fistula; the risk of rebleeding is very low and the prognosis is good. Other causes rarely reported include rupture of a cerebral AVM, dural AVF, cerebral vasculitis, cocaine abuse, coagulation disorders, moyamoya disease, and vertebral artery dissection.

Reported triggers of rupture include activities that cause a sudden rise in blood pressure—straining (Valsalva), sexual activity, strenuous exercise, excitement or fear, and drinking—but rupture also occurs during sleep or at rest. Smoking, hypertension, and excessive drinking are the main risk factors increasing the risk of aneurysm formation and rupture.


3. Genetics

Genetic factors play an important role in cerebral aneurysm. In families with two or more first-degree relatives with aneurysm or SAH, the risk of cerebral aneurysm is about 4~7 times higher than in the general population.

Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in the PKD1 (16p13) or PKD2 (4q21-23) gene, and the prevalence of cerebral aneurysm in ADPKD patients is about 5 times that of the general population (about 8~12%). Some guidelines recommend brain MRA screening when there is a family history of ADPKD. In vascular Ehlers-Danlos syndrome (vEDS) (COL3A1 mutation), the risk of aneurysm rupture is significantly increased. In neurofibromatosis type 1 (NF1) (NF1 mutation), the risk of vascular dysplasia and aneurysm is increased.

Genome-wide association studies (GWAS) of sporadic cerebral aneurysm have identified association signals at several loci, including CDKN2A/CDKN2B (9p21), RBBP8, SOX17, EDNRA, and STARD13/KL. These genes are related to vessel wall structure, cell cycle regulation, and endothelial cell function. However, to date there is insufficient evidence to recommend genetic testing for individual risk prediction in clinical practice, and testing is performed selectively only when a genetic syndrome is suspected.


4. General epidemiology

Subarachnoid hemorrhage accounts for about 1~7% of all strokes but accounts for a substantial proportion of stroke deaths and disability in younger age groups. The worldwide annual incidence is estimated at about 6~9 per 100,000 population, varying by region. Particularly high incidence (about 10~20/100,000) is reported in Finland and Japan.

The incidence in Korea is reported at about 10~15 per 100,000 in analyses of National Health Insurance big data, somewhat higher than the global average. By sex, incidence is slightly higher in women (female:male = about 1.3~1.6:1). By age, it occurs most often at 40~65 years, and a characteristic feature is that occurrence in young adults is relatively more common than in other stroke types.

Major risk factors include smoking (relative risk about 2~3 times), hypertension (relative risk about 2~4 times), excessive drinking, family history (SAH or cerebral aneurysm in first-degree relatives), female sex, and oral contraceptive use. The prevalence of unruptured cerebral aneurysm is estimated at about 1~5% of the general population, and the overall annual rupture rate among these is about 0.5~1.5%, but it varies greatly with aneurysm size, location, and morphology.


5. Pathophysiology

The pathophysiology of subarachnoid hemorrhage due to aneurysm rupture is understood in two phases: early brain injury (EBI) and delayed complications.

Early brain injury (EBI, within 72 hours): when an aneurysm ruptures, arterial blood gushes rapidly into the subarachnoid space, raising intracranial pressure (ICP) sharply to tens of mmHg or more, and transient ischemia occurs in which cerebral perfusion pressure (CPP) momentarily approaches 0. In this process, global cerebral ischemia, cellular edema, excitotoxin release, blood–brain barrier (BBB) disruption, and neuroinflammation occur in cascade. The severity of early brain injury is closely related to the initial level of consciousness and is a major determinant of neurological status on admission.

Rebleeding: with an untreated aneurysm, the risk of rebleeding within the first 24 hours is about 4~14%, and mortality with rebleeding reaches 50~80%. This is the key rationale for early aneurysm treatment.

Cerebral vasospasm and delayed cerebral ischemia (DCI): a delayed complication in which vasoconstriction occurs 4~14 days (mainly 7~10 days) after hemorrhage, resulting in cerebral ischemia. Oxyhemoglobin released from subarachnoid blood, overexpression of endothelin-1 (ET-1), decreased nitric oxide (NO), inflammatory mediators, and others are the causes of vasospasm. Clazosentan (an ET-A receptor antagonist) has shown an effect in reducing vasospasm and has recently begun to be included in clinical guidelines. Hydrocephalus: when blood blocks the arachnoid granulations and cerebrospinal fluid (CSF) absorption is impaired, communicating hydrocephalus develops, and with intraventricular hemorrhage, obstructive hydrocephalus may appear.


6. Symptoms

The most characteristic symptom of aneurysmal SAH is a sudden excruciating headache. Patients often describe it as "the worst headache of my life" or "a headache like being hit on the head with a hammer (thunderclap headache)." This headache peaks within seconds and lasts hours to days.

Accompanying symptoms of nausea and vomiting (about 75%), neck stiffness (meningeal irritation), photophobia, and phonophobia are common. Loss of consciousness (transient or persistent) reflects the severity of the initial hemorrhage, and about 10~25% fall into a coma before hospital arrival. Seizures (about 20%) may occur early. Focal neurological deficits vary with the hemorrhage site and hematoma formation, and with a posterior communicating artery aneurysm, ipsilateral third cranial nerve palsy (ptosis, pupillary dilation, exotropia) may appear.

Sentinel headache: a mild to moderate headache of the same character may occur days to weeks before the major rupture and resolve spontaneously. This appears to reflect a minor leak or rapid expansion of the aneurysm, and about 20~50% of SAH patients are reported to have experienced a sentinel headache. It is clinically important because recognizing a sentinel headache and seeking medical care in time make preventive treatment possible.


7. Signs

On physical examination of subarachnoid hemorrhage, the following characteristic signs appear.

Meningeal signs: nuchal rigidity is the most important physical examination finding, with resistance felt on passive neck flexion. Nuchal rigidity may not appear within the first few hours after onset. Kernig's sign (pain and resistance on knee extension after 90° hip flexion) and Brudzinski's sign (automatic flexion of both hips and knees on passive neck flexion) are positive.

Level of consciousness: assessed with the Hunt-Hess classification or WFNS (World Federation of Neurosurgical Societies) grade. The degree of GCS decline is an important determinant of early prognosis. Pupillary abnormalities: with rupture of a posterior communicating artery aneurysm, compression of the ipsilateral third cranial nerve causes pupillary dilation, ptosis, and exotropia. Bilateral fixed, dilated pupils suggest severe intracranial pressure elevation or brainstem injury.

Terson syndrome: intravitreal or subretinal hemorrhage due to a sudden rise in intracranial pressure, identified on fundoscopy in about 10~40% of SAH patients. ECG abnormalities (QT prolongation, ST changes, T-wave inversion, U waves) are observed in about 50~100% of SAH patients and reflect neurogenic cardiac injury due to a catecholamine surge. Takotsubo cardiomyopathy may accompany it, so echocardiographic evaluation is needed.


8. Screening

When subarachnoid hemorrhage is suspected, rapid diagnosis is decisive for saving life.

Non-contrast brain CT is the first-line diagnostic tool. CT sensitivity within 6 hours of SAH onset is about 98~100% and decreases with time (about 90% after 24 hours, about 50% after 1 week). On CT, SAH is identified by hyperdensity in the basal cisterns, Sylvian fissure, and between the gyri. Lumbar puncture is performed when CT is negative but SAH is strongly suspected. Xanthochromia in the CSF (yellow tint of the supernatant after centrifugation) confirms SAH and is observed from 12 hours to 2 weeks after onset. Xanthochromia should be interpreted together with the CSF red cell count.

With the latest CT protocols, there are studies showing that the negative predictive value of non-contrast CT for SAH within 120 hours (5 days) is high enough that SAH can be excluded without lumbar puncture, but this should be applied together with clinical judgment. After SAH is confirmed, the causative aneurysm is evaluated immediately with CTA or DSA.


9. Diagnosis

After SAH is diagnosed, tests are performed to evaluate the cause and grade severity.

CT angiography (CTA) is a rapid noninvasive test for identifying aneurysms, with sensitivity of 90~98% and specificity of 95~100%. DSA is needed for small aneurysms (< 3 mm) or special locations. Digital subtraction angiography (DSA) is the standard for aneurysm diagnosis and most accurately assesses size, morphology, neck shape, relationship with feeding arteries, and associated vascular abnormalities. It can be performed simultaneously with treatment (coil embolization).

Severity grading scales:

After admission, continuous monitoring in the neuro-intensive care unit (neuro-ICU)—ECG, blood pressure, pulse oximetry, ETCO2, body temperature—is performed together with intracranial pressure (ICP) monitoring (if needed) and assessment of vasospasm by transcranial Doppler (TCD).


10. Treatment

Intensive care of subarachnoid hemorrhage (V268 applies: intensive care unit inpatient management) consists of three pillars: early aneurysm treatment, prevention and management of complications, and brain protection.

Early aneurysm treatment is recommended as soon as possible after diagnosis of SAH (within 24~72 hours) to prevent rebleeding. Endovascular coiling is preferred over clipping for aneurysms with suitable anatomy based on the ISAT results. For wide-neck or complex aneurysms, stent-assisted coiling, flow diverters, and the like are used. Surgical clipping is chosen for aneurysms in accessible locations, cases requiring immediate decompression due to accompanying intracerebral hematoma, and aneurysms not amenable to coil embolization.

Prevention of vasospasm and delayed cerebral ischemia: oral or intravenous nimodipine (60 mg every 4 hours for 21 days) is recommended as standard treatment and improves neurological outcomes. Clazosentan has been shown to reduce the incidence of vasospasm and has been included in some guidelines. Induced hypertension, hemodilution, and hypervolemia (Triple-H therapy) have now been withdrawn from standard treatment, and maintenance of euvolemia and induced hypertension when needed are recommended. Vasospasm is monitored with TCD, and for symptomatic vasospasm, balloon angioplasty or intra-arterial vasodilators (nicardipine, verapamil, papaverine) are used. Management of hydrocephalus: in acute hydrocephalus, external ventricular drainage (EVD, external ventricular drain) controls ICP and contributes to improved consciousness. Chronic hydrocephalus is treated with cerebrospinal fluid shunting (VP shunt, LP shunt). Other intensive care: includes blood glucose control (target 140~180 mg/dL), fever prevention (maintaining below 37.5°C), prophylactic seizure treatment (if needed), and cardiac monitoring and myocardial protection.


11. Prognosis

The prognosis of aneurysmal SAH remains poor, with overall mortality of about 25~50%. Deaths before hospital arrival account for about 10~15%, and mortality within 30 days of admission is about 25~35%. Long-term cognitive, behavioral, and psychological impairment persists in about 30~50% of survivors.

Poor prognostic factors include low initial GCS (Hunt-Hess 4~5 or WFNS 4~5), older age, rebleeding, severe vasospasm and delayed cerebral ischemia, intraventricular hemorrhage, intracerebral hematoma, Fisher grade 3~4, and systemic complications (hyponatremia, heart failure, pneumonia). Prognosis has improved over the past decades with advances in early aneurysm treatment and neuro-intensive care unit management, but high mortality and disability rates remain a challenge.

The prognosis of non-aneurysmal PMSAH is markedly favorable, with 30-day mortality of about 0~5% and neurological recovery mostly complete. Among patients who survive after aneurysm treatment, the proportion achieving functional independence (mRS 0~2) after overcoming vasospasm is about 50~70%. Prognosis is much poorer with recurrent (re-ruptured) aneurysms.


12. Prevention

Prevention of subarachnoid hemorrhage is divided into primary prevention (prevention of aneurysm formation and rupture) and secondary prevention (prevention of recurrence after treatment).

In primary prevention, control of modifiable risk factors is key. Smoking cessation is the single lifestyle improvement that most effectively reduces the risk of aneurysm formation and rupture, and smokers have about 2~3 times higher SAH risk than nonsmokers. Hypertension control (target < 130/80 mmHg) reduces the mechanical stress on the aneurysm wall, lowering the risk of rupture. Limiting excessive drinking also contributes to reducing SAH risk. For selective cerebrovascular screening, brain MRA screening can be considered when two or more first-degree family members have SAH or cerebral aneurysm. Aneurysm screening is also recommended in ADPKD patients. Treatment decisions for incidentally found unruptured cerebral aneurysms are made by a multidisciplinary team, comprehensively considering aneurysm size, location, patient age and general condition, and procedural risk. Natural history data such as the ISUIA study (International Study of Unruptured Intracranial Aneurysms) are used in decision-making.


13. References

  1. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737. DOI: 10.1161/STR.0b013e3182587839. PMID: 22556195.

  2. Molyneux AJ, Kerr RS, Birks J, et al. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. Lancet Neurol. 2009;8(5):427-433. DOI: 10.1016/S1474-4422(09)70080-8. PMID: 19329361.

  3. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping (CONSCIOUS-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2011;10(7):618-625. DOI: 10.1016/S1474-4422(11)70108-9. PMID: 21640651.

  4. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391-2395. DOI: 10.1161/STROKEAHA.110.589275. PMID: 20798370.

  5. Steyerberg EW, Harrell FE Jr, Habbema JD. Prognostic modelling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Decis Making. 2001;21(1):45-56. DOI: 10.1177/0272989X0102100106. PMID: 11206946.

  6. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306-318. DOI: 10.1016/S0140-6736(07)60153-6. PMID: 17258671.

  7. Diringer MN, Bleck TP, Claude Hemphill J 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211-240. DOI: 10.1007/s12028-011-9605-9. PMID: 21773873.

  8. Frontera JA, Claassen J, Schmidt JM, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified Fisher scale. Neurosurgery. 2006;59(1):21-27. DOI: 10.1227/01.NEU.0000218821.34014.1B. PMID: 16823296.

  9. Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103-110. DOI: 10.1016/S0140-6736(03)13860-3. PMID: 12867109.

  10. Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med. 2006;34(3):617-623. DOI: 10.1097/01.CCM.0000200966.14012.3B. PMID: 16521253.